APLLTD:NSE-Alembic Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 739.15

Change

-2.40 (-0.32)%

Market Cap

INR 145.50B

Volume

0.15M

Avg Analyst Target

INR 787.67 (+6.56%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Alembic Pharmaceuticals Limited (APLLTD) Stock Analysis:
Based on the Alembic Pharmaceuticals Limited stock forecasts from 3 analysts, the average analyst target price for Alembic Pharmaceuticals Limited is INR 787.67 over the next 12 months. Alembic Pharmaceuticals Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Alembic Pharmaceuticals Limited is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Alembic Pharmaceuticals Limited’s stock price was INR 739.15. Alembic Pharmaceuticals Limited’s stock price has changed by +1.87% over the past week, -4.03% over the past month and -21.29% over the last year.

About

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (API) and formulations. The company also provides branded and generic formulations in various therapeutic areas, s ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+3.10 (+0.35%)

INR2,134.56B 33.23 20.01
DIVISLAB:NSE Divi's Laboratories Limited

-63.00 (-1.47%)

INR1,135.58B 44.22 30.88
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-35.90 (-0.91%)

INR644.99B 24.55 12.99
PEL:NSE Piramal Enterprises Limited

+63.35 (+3.50%)

INR446.10B 35.96 11.39
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-1.35 (-0.05%)

INR440.83B 36.15 17.45
ALKEM:NSE Alkem Laboratories Limited

+0.65 (+0.02%)

INR350.67B 19.72 15.69
AUROPHARMA:NSE Aurobindo Pharma Limited

-11.45 (-2.04%)

INR322.21B 11.24 6.71
LUPIN:NSE Lupin Limited

-11.30 (-1.62%)

INR311.81B 25.10 35.37
LAURUSLABS:NSE Laurus Labs Limited

+4.35 (+0.81%)

INR289.42B 35.08 21.31
IPCALAB:NSE IPCA Laboratories Limited

+8.25 (+0.85%)

INR247.92B 27.09 16.94

ETFs Containing APLLTD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.83% 84% B 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.83% 81% B- 58% F
Trailing 12 Months  
Capital Gain -21.67% 39% F 14% F
Dividend Return 1.48% 100% A+ 66% D
Total Return -20.19% 42% F 14% F
Trailing 5 Years  
Capital Gain 21.27% 41% F 55% F
Dividend Return 4.51% 85% B 59% F
Total Return 25.78% 43% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain 16.45% 37% F 51% F
Dividend Return 0.76% 77% C+ 53% F
Total Return 17.21% 35% F 50% F
Risk Return Profile  
Volatility (Standard Deviation) 36.58% 78% C+ 75% C
Risk Adjusted Return 47.05% 54% F 70% C-
Market Capitalization 145.50B 85% B 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.12 59% F 50% F
Price/Book Ratio 2.73 52% F 39% F
Price / Cash Flow Ratio 26.34 32% F 24% F
EV/EBITDA 16.14 43% F 38% F
Management Effectiveness  
Return on Equity 17.63% 58% F 70% C-
Return on Invested Capital 10.49% 49% F 67% D+
Return on Assets 8.51% 62% D- 76% C
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 1.89% 98% A+ 75% C
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.74 53% F 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector